+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Abatacept"

From
Rheumatoid Arthritis Drugs Market Report 2025 - Product Thumbnail Image

Rheumatoid Arthritis Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Myositis - Pipeline Insight, 2025 - Product Thumbnail Image

Myositis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
IgG4-Related Disease - Pipeline Insight, 2025 - Product Thumbnail Image

IgG4-Related Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Vitiligo Pipeline Analysis Report - Product Thumbnail Image

Vitiligo Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
US Alopecia Areata - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

US Alopecia Areata - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • November 2023
  • 115 Pages
  • United States
From
ORENCIA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

ORENCIA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Abatacept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It works by blocking the activity of a molecule called CTLA-4, which is involved in the body's immune response. Abatacept is administered through an intravenous infusion or subcutaneous injection. It is used to reduce inflammation and pain associated with these conditions, as well as to slow down the progression of joint damage. Abatacept is a relatively new drug, having been approved by the US Food and Drug Administration in 2005. It is one of several biologic drugs used to treat immune disorders, and is often used in combination with other medications. Some companies in the Abatacept market include Bristol-Myers Squibb, AstraZeneca, and Pfizer. Show Less Read more